Q4 2018 Investor Presentation

Improving Adherence to Therapy ResAdhere: remote monitoring + mask resupply drive improved adherence In a study of ~100k patients with AirView cloud-connected devices... Probability on Therapy (%) 100 100% 0 Resupply group (AirView + Brightree) Control group (non-resupply) 90 Time to Drop out (days) + brightree. AirView™ 84% 66% 360 ...the likelihood of therapy termination decreased by >50% after one-year and there was a significant increase in daily PAP usage Benjafield, et al. AJRCCM 2018 (abstract) Note: De-identified data from Brightree and AirView were sent to a third-party independent statistician who provided the anonymized analyses and findings. ©2018 ResMed | Q4 2018 Investor Presentation | 18 ResMed

View entire presentation